Join Rectify Pharma for a virtual R&D event to discuss positive functional modulators (PFMs) as a novel small molecule modality to restore and enhance protein function, the role of ABCB4 and BSEP transporter proteins in driving the core pathophysiology of PSC, clinical presentation and unmet need in PSC, and advancement of RTY-694, an orally available ABCB4/BSEP dual targeted PFM for the treatment of PSC, toward the clinic.

The event will feature presentations from the following key opinion leaders (KOLs):

• Robert A. Copeland, PhD – Rectify Scientific Advisory Board member and President and CSO of Accent Therapeutics
• Kris Kowdley, MD, FACP, FACG, AGAF, FAASLD – Professor at Elson S. Floyd College of Medicine at Washington State University
• Richard J. Thompson, BM BCh, DM – Rectify Scientific Advisory Board member and Professor at Institute of Liver Studies at King’s College London

Company management will also provide an overview of Rectify’s breakthrough PFM product platform, additional programs and future directions.

A live question and answer session will follow the formal presentations.